UPSTREAM BIO
Upstream Bio focuses on developing an antibody therapy for the treatment of severe asthma. They are clinical-stage monoclonal antibodies that inhibit the TSLP receptor, a validated target located upstream of various signaling cascades that influence a range of immune cells that are important in common and unusual illnesses.
UPSTREAM BIO
Industry:
Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
2021-01-01
Address:
Waltham, Massachusetts, United States
Country:
United States
Website Url:
http://www.upstreambio.com
Total Employee:
11+
Status:
Active
Contact:
+1-800-539-0289
Email Addresses:
[email protected]
Total Funding:
408 M USD
Technology used in webpage:
Squarespace Hosted Twitter Timeline
Similar Organizations
BioInvenu
BioInvenu is a biotechnology research company.
Celavie Biosciences
Celavie Biosciences is a biotechnology research company.
EternaTear
EternaTear is developing a next-generation therapy for the over-the-counter dry eye market.
Gene Sciences, Inc.
Gene Sciences Inc. is developing novel DNA targeted therapeutics for the treatment of human genetic diseases.
Integrated BioTherapeutics
AIntegrated BioTherapeutics is a focused on the discovery of novel vaccines and therapeutics for emerging infectious diseases.
Ladder Therapeutics
Ladder Therapeutics is a biotechnology research company.
PvP Biologics
PvP Biologics is developing an oral enzyme for the treatment of celiac disease.
SoyMeds
SoyMeds is a biotechnology research company
Current Advisors List
Current Employees Featured
Founder
Investors List
Wellington Management
Wellington Management investment in Series B - Upstream Bio
Access Biotechnology
Access Biotechnology investment in Series B - Upstream Bio
Bain Capital Life Sciences
Bain Capital Life Sciences investment in Series B - Upstream Bio
HBM Partners
HBM Partners investment in Series B - Upstream Bio
Decheng Capital
Decheng Capital investment in Series B - Upstream Bio
HBM Healthcare Investments
HBM Healthcare Investments investment in Series B - Upstream Bio
Samsara BioCapital
Samsara BioCapital investment in Series B - Upstream Bio
Enavate Sciences
Enavate Sciences investment in Series B - Upstream Bio
Venrock Healthcare Capital Partners
Venrock Healthcare Capital Partners investment in Series B - Upstream Bio
Altshuler Shaham
Altshuler Shaham investment in Series B - Upstream Bio
Key Employee Changes
| Date | New article |
|---|---|
| 2024-04-02 | Upstream Bio Announces Appointment of Rand Sutherland as CEO and Additions to Leadership Team |
Official Site Inspections
http://www.upstreambio.com Semrush global rank: 5.26 M Semrush visits lastest month: 1.47 K
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Upstream Bio"
About - Upstream Bio
At Upstream Bio, we are developing treatments for inflammatory diseases. We are developing verekitug, the only known antagonist currently in development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP). We have โฆSee details»
Team | Upstream Bio
Our leadership team and board of directors have significant experience developing and commercializing innovative medicines, with deep expertise in severe asthma and other โฆSee details»
Upstream Bio
Jan 13, 2025 Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. Upstream Bio is โฆSee details»
Upstream Bio - Crunchbase Company Profile & Funding
Upstream Bio focuses on developing an antibody therapy for the treatment of severe asthma.See details»
Upstream Bio - LinkedIn
Upstream Bio | 7,708 followers on LinkedIn. Developing treatments for inflammatory diseases | We are advancing verekitug, a clinical-stage monoclonal antibody targeting an upstream driver of ...See details»
Upstream Bio, Inc. (UPB) Company Profile & Facts - Yahoo Finance
See the company profile for Upstream Bio, Inc. (UPB) including business summary, industry/sector information, number of employees, business summary, corporate governance, โฆSee details»
Upstream Bio (UPB) Company Profile & Description
Oct 11, 2024 Company profile for Upstream Bio, Inc. (UPB) stock, with a description, list of executives, contact details and other key facts.See details»
Upstream Biosciences Inc. - VentureRadar
At Upstream Bio we strive to reach the source of inflammation and conquer it. Our lead program is aclinical-stage monoclonal antibody that inhibits the TSLP receptor. TSLP is a validated target โฆSee details»
Upstream Bio - workinbiotech.com
Upstream Bio is dedicated to leveraging advanced scientific techniques in cellular and molecular biology to address inflammatory and allergic diseases. Their mission focuses on developing โฆSee details»
Investor FAQs โ Upstream Bio
Find answers to common investor questions about Upstream Bio.See details»
Upstream Bio 2025 Company Profile: Stock Performance
Information on stock, financials, earnings, subsidiaries, investors, and executives for Upstream Bio. Use the PitchBook Platform to explore the full profile.See details»
Upstream Bio Announces $200M Series B Financing to ... - Enavate โฆ
Jun 8, 2023 To learn more about Enavate, please visit www.enavatesciences.com. Company Contact Jennifer Beachell โ Chief Operating Officer [email protected] Media Contact โฆSee details»
Upstream Bio, Inc. (Upstream Bio, Inc.) - ่ฏ็ฉ็ฎก็บฟ_ไธๅฉ_ไธดๅบ่ฏ้ช_ โฆ
Upstream Bioโs team is committed to maximizing verekitugโs unique attributes to address the substantial unmet needs for patients underserved by todayโs standard of care. To learn more, โฆSee details»
Upstream Bio Announces $200M Series B Financing to Advance โฆ
Jun 8, 2023 To learn more about Enavate, please visit www.enavatesciences.com. Company Contact Jennifer Beachell Chief Operating Officer [email protected] Media Contact โฆSee details»
UPSTREAMBIO
Upstreambio has been consistently making the latest technologies and advances. Based on Intestinal Microorganisms, Our company is developing microbiome-based treatments. It โฆSee details»
Upstream Bio to Present at the 43rd Annual J.P. Morgan โฆ
WALTHAM, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus โฆSee details»
Upstream Bio - Craft
Oct 29, 2024 Upstream Bio is a clinical-stage biotechnology company that develops treatments for inflammatory diseases. It focuses on severe respiratory disorders, such as asthma, COPD, โฆSee details»
Upstream Bio Launches with $200M Series A Financing to Advance โฆ
Jun 2, 2022 Clinical-stage program UPB-101 targets the TSLP receptor, a cytokine receptor positioned upstream in the inflammatory cascade with the potential to impact multiple โฆSee details»
Upstream Bio Announces Oral Presentation of New Data from a โฆ
Sep 9, 2024 Upstream Bio Announces Oral Presentation of New Data from a Phase 1b Multiple Ascending Dose Trial of Verekitug (UPB-101) in Adults with Asthma at the European โฆSee details»